Clinical trials almost unanimously point to the activation of both humoral (facilitated by CD4+ T-cells) and cellular immune responses (mostly by the activation of CD8+ T-cells) following DNA vaccination which means many different mechanisms work synergistically to eliminate the tumor. The gene discussed is CD8A; the disease is neoplasm.